Endocrine Pancreatic Tumors in von Hippel-Lindau Disease: Clinical, Histological, and Genetic Features

Objectives: Endocrine pancreatic tumors (EPTs) in von Hippel-Lindau (VHL) disease pose difficult management problems. We aimed to assess (1) the accuracy of somatostatin receptor scintigraphy, (2) histological features with focus on malignancy and genotype-phenotype correlations, and (3) prognosis of VHL-EPT. Methods: Thirty-five patients with EPT-VHL (20 women; median age, 37 years) from 29 families were studied. Histological diagnosis was available in 29 patients. Endocrine pancreatic tumor patients were treated surgically (n = 22), medically (n = 8), or followed (n = 5). Somatostatin receptor scintigraphy was performed in 27 patients. Germinal alterations of the VHL gene were determined. Results: Tumors were malignant in 58% of patients. Somatostatin receptor scintigraphy was positive in 60% of cases, and weak expression of the somatostatin receptor type 2A was found in 47% of tumors. In operated patients, there was no mortality or tumor relapse (median follow-up, 5 [1-10] years). Mortality rate due to EPT was 6%. Germinal mutations were mainly located in exons 3 and 1, and a specific mutation (P86S) was identified. Conclusions: Most EPTs in VHL patients are somatostatin receptor scintigraphy-positive and malignant, without correlation with the VHL genotype. Surgical resection is often required, but prognosis of these EPTs seems to be fairly good.Abbreviations: CNS - central nervous system, CT scan - computed tomography, EPT - endocrine pancreatic tumors, EUS - endoscopic ultrasonography, SRS - somatostatin receptor scintigraphy, VHL - von Hippel-Lindau disease

[1]  A. Scarpa,et al.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.

[2]  A. Harris,et al.  Expression of hypoxia‐inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas , 2005, Histopathology.

[3]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Yenigun,et al.  Pancreatic involvement in Von Hippel-Lindau disease. , 2004, Indian journal of cancer.

[5]  B. Taouli,et al.  Spectrum of abdominal imaging findings in von Hippel-Lindau disease. , 2003, AJR. American journal of roentgenology.

[6]  S. Libutti,et al.  Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. , 2002, Radiology.

[7]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[8]  C. Bordi,et al.  [Guidelines and minimal diagnostic criteria for the histological diagnosis of endocrine tumors of the gastroenteropancreatic type]. , 2002, Pathologica.

[9]  A. Ochiai,et al.  Prognostic Significance of Fibrotic Focus in Invasive Ductal Carcinoma of the Breast: A Prospective Observational Study , 2002, Modern Pathology.

[10]  E. Krenning,et al.  Somatostatin receptor imaging. , 2002, Seminars in nuclear medicine.

[11]  M. Papotti,et al.  Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors , 2002, Virchows Archiv.

[12]  S. Libutti,et al.  Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. , 2000, Surgery.

[13]  Michelle A. Anderson,et al.  Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas , 2000, American Journal of Gastroenterology.

[14]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[15]  S K Libutti,et al.  Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. , 1998, Surgery.

[16]  M. Schubert.  Somatostatin receptor scintigraphy: A first–line imaging modality for gastroenteropancreatic neuroendocrine tumors , 1998 .

[17]  V. Vilgrain,et al.  Prognostic factors in patients with endocrine tumours of the duodenopancreatic area , 1998, Gut.

[18]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[19]  S. Libutti,et al.  Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. , 1998, The American journal of pathology.

[20]  J. Mosnier,et al.  The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. , 1998, American journal of clinical pathology.

[21]  R. Klausner,et al.  The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Sessa,et al.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours , 1996, Virchows Archiv.

[23]  G. Pelosi,et al.  Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. , 1996, Human pathology.

[24]  D. Le Guludec,et al.  Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. , 1996, Gastroenterology.

[25]  D. Venzon,et al.  Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study , 1996, Annals of Internal Medicine.

[26]  R. Klausner,et al.  Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Fléjou,et al.  Variété des lésions pancréatiques observées au cours de la maladie de von Hippel-Lindau. Présentation de 8 cas. , 1995 .

[28]  Takuro Nakamura,et al.  Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. , 1995, Internal medicine.

[29]  P. Ruszniewski,et al.  Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. , 1995, Surgery.

[30]  F. Jamar,et al.  Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  P. Choyke,et al.  von Hippel-Lindau disease: genetic, clinical, and imaging features. , 1995, Radiology.

[32]  M. Lerman,et al.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.

[33]  G. Cadiot,et al.  Somatostatin-receptor scintigraphy in endocrine tumors. , 1994, Gastroenterology.

[34]  G. Cadiot,et al.  Somatostatin-recoptor scintlgraphy in endocrine tumors , 1994 .

[35]  D. Hough,et al.  Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. , 1994, AJR. American journal of roentgenology.

[36]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[37]  C. Lightdale,et al.  Localization of pancreatic endocrine tumors by endoscopic ultrasonography. , 1992, The New England journal of medicine.

[38]  H. Brambs,et al.  Pancreatic lesions in the von Hippel-Lindau syndrome. , 1991, Gastroenterology.

[39]  von Hippel-Lindau disease , 1991, The Lancet.

[40]  C. Johnson,et al.  Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. , 1990, AJR. American journal of roentgenology.

[41]  S. Richard,et al.  Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. , 2000, Gastroenterology.

[42]  L. Sobin,et al.  Histological Typing of Endocrine Tumours , 2000, International Histological Classification of Tumours.

[43]  W. Linehan,et al.  Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.

[44]  Christophe Béroud,et al.  Software and database for the analysis of mutations in the VHL gene , 1998, Nucleic Acids Res..

[45]  D. Le Guludec,et al.  Somatostatin receptor scintigraphy: a first-line imaging modality for gastroenteropancreatic neuroendocrine tumors. , 1998, Gastroenterology.

[46]  W. Linehan,et al.  Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.

[47]  S. Richard,et al.  [Variety of pancreatic lesions observed in von Hippel-Lindau disease. Apropos of 8 cases]. , 1995, Gastroenterologie clinique et biologique.